A Phase 4 interventional study of Contrave and Placebo in Obesity, Weight Loss and Weight Management, sponsored by The Royal's Institute of Mental Health Research. Recruiting at 3 sites in Canada. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by The Royal's Institute of Mental Health Research · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 575 studies in Obesity with a site in Canada — 102 open to participants now, 151 under way, 47 of them phase 3. Obesity · Canada.
Among the 575 studies in Obesity with a site in Canada, this one is the 328th largest by planned enrollment of the 480 interventional ones that give a count, is one of 27 that started in 2024, is one of 26 in phase 4, reaches primary completion later than 34 of the 150 other live ones, and was the 489th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →102 of the 575 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+ · Women only
McMaster University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
575 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 63 · Phase 3 98 · Phase 4 26
First in 1997; this study’s year is marked. 27 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 74 across the 480 interventional studies, 52 across the 91 observational. Of the 362 that completed or were terminated, 49 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 575 have an industry lead sponsor. The 10 most frequent:
The Royal's Institute of Mental Health Research is the lead sponsor of 7 studies on the registry; 6 are open to participants now.
The Royal's Institute of Mental Health Research has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
46 of the studies in Obesity with a site in Canada that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 575 studies in Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues (e.g., smelling), higher food liking and craving, and a drop in resting energy expenditure (REE). REE has been shown to predict weight regain.
The standard care for obesity may include the use of the weight-loss drug CONTRAVE®. The Federal Drug Agency (FDA) and Health Canada have approved this drug for weight management and obesity treatment.
Although CONTRAVE® was designed to reduce appetite, food-related impulsivity and cravings, its mechanisms of action are unclear. In other words, the effects of CONTRAVE® on REE, executive function, and brain changes remain unknown in humans. A better understanding of how this drug works on the brain and body could lead to improvements in obesity management in the future.
As such, the goal of this research is to study the effects of 4 weeks of CONTRAVE® (+ diet program) vs. control (placebo pill + diet program) on mood, body composition changes, biological/metabolic measures, and brain measures.
Adults aged 18-64 with obesity will be randomized to one of two groups: diet + CONTRAVE® (CONTRAVE®, 20 participants) or diet + Placebo (Placebo, 20 participants). Both groups will be assigned the same study procedures for the entire study duration. The only difference is that Group 1 will receive CONTRAVE® while Group 2 will receive a placebo (non-medical) pill.
The study design and intervention is as follows:
Participants who meet all the telephone screening criteria will be invited to the Clinical EEG \& Neuroimaging Laboratory at The Royal's IMHR for an in-person screening and test-dose session. Participants who are cleared by the study physician, Dr. Pierre Blier, during the in-person screening will be enrolled in the 4-weeks trial.
After the in-person screening visit, participants will attend two baseline testing visits (before starting the medication + diet program). The first will occur at the Behavioural and Metabolic Research Unit at the University of Ottawa. During this in-person visit, measures of body composition, resting energy expenditure, appetite, food craving, impulsivity, eating behaviours, taste and odour sensitivity, energy intake, and food preference will be collected.
The second baseline visit (within a week of the first one) will occur at The Royal/IMHR. During this visit, participants will be asked to complete questionnaires. They will undergo an EEG recording while resting and performing computer tasks. They will also get a brain imaging scan, during which they are asked to rest and complete a computer task.
Both testing sessions (University of Ottawa and Royal Ottawa testing sessions) will be repeated after four weeks of treatment. The section below provides further description and timing of these visits.
As part of the treatment, you will receive an individualized dietary intervention with appropriate energy restriction from a registered dietitian at Dr. Judy Shiau's LEAF weight management clinic (called the 4-week BUDS program). The program involves weekly touch points with a registered dietitian and meal planning/coaching. The diet intervention will commence the same week as the start of the placebo/CONTRAVE®.
During the 4-week intervention, participants will be asked to complete online questionnaires at various times.
Detailed Description
This study is a two-arm, randomized, double-blind, placebo-controlled design, wherein N=40 adults aged 18-64 years with obesity (body mass index [BMI] > 30) and who meet all inclusion criteria (outlined below) will be randomized to one of two groups: Diet + CONTRAVE® (CONTRAVE®, N=20) or diet + Placebo (Placebo, N=20).
Participants will be randomized 1:1 per condition using a randomization program (computer-program). Each participant will be assigned a unique identifier code. Master codes containing the link between the identification code and name of the individual will be stored on a password-protected master file (excel) that will be saved on hospital servers (password-protected) in the Clinical EEG \& Neuroimaging Laboratory (Co-PI: N. Jaworska). All hard-copies of confidential information (e.g., screening documents, consent forms) will be housed in secured cabinets within the Clinical EEG Laboratory.
Recruitment for this study will occur from Dr. J. Shiau's LEAF Weight Management Clinic. Following initial assessment of needs, a staff member of the LEAF clinic will mention this study and ask interested individuals to complete an online form as initial registration in the study. These potential participants will be contacted by research staff who are not affiliated with the LEAF clinic (i.e., research assistant or trainees who are part of the research team); the research personnel will then phone interested participants to explain the study and associated risks and benefits of participating. Participants who do not wish to participate in the research study after details are provided, will continue with the normal intake process at the LEAF clinic. Participants who wish to participate will complete a telephone screening questionnaire with the research staff. Eligible participants will be booked for an in-person screening session at The Royal Ottawa Mental Health Centre.
Screening and Testing Sessions Overview:
Participants will have 5 in-person laboratory visits (Clinical EEG \& Neuroimaging Laboratory, under the direction of Dr. Natalia Jaworska, at The Royal/IMHR; and, Behavioural and Metabolic Research Laboratory, under the direction of Dr. Eric Doucet, at the University of Ottawa). Specifically,
Phone Screening:
Participants will be recruited from the LEAF clinic. Those who are interested in participating complete an online registration form. They will then be contacted by research study personnel and screened over the phone, regarding basic inclusion criteria. The study will also be explained. Following successful phone screening, an in-person screening visit and test dose (administered by The Royal pharmacy and overseen by Dr. Pierre Blier) visit will be scheduled at the IMHR (Dr. Jaworska's laboratory). Only participants who have been cleared medically by the LEAF clinic/Dr. Judy Shiau will be referred to this study.
In Person Screening:
This will occur at The Royal. The informed consent will be carried out, and any questions will be addressed and documented directly on the consent form. Second, a brief clinical assessment (to ensure that outstanding inclusion and exclusion criteria are met), using modules from the MINI (Mini International Neuropsychological Inventory) including the mood module, substance use module, psychotic disorders module, and eating disorders module (approximately 30min). Heart rate and blood pressure will then be measured reviewed by Dr. Pierre Blier.
Test Dose Administration (as part of In Person Screening Session):
Subsequently (during the in-person screening), The Royal's pharmacy would issue one test dose of the drug placebo or CONTRAVE® based on the participant drug randomization. This pill would be given to the participant. The test dose will be 1 tablet of placebo or CONTAVE® (8mg Naltrex/90 mg Buproprion). The participant and study doctor and research staff will be blind to treatment (they will not know whether they will be given CONTRAVE® or placebo). Only research personnel from the laboratory -not directly related to this study- and the pharmacy team will know what the randomization is (i.e., what participant is receiving what drug). The participant would take the pill along with crackers/light snack in Dr. Blier's laboratory (as CONTRAVE® should be taken with food) and watch a movie and/or read a book or work (participant preference) for 3 hours in one of the examination chambers in the Mood Disorders Unit.
After 3 hours of ingesting the test dose, and -at that time- exhibiting no/minimal adverse symptoms (i.e., most common adverse events symptoms include nausea, vomiting, constipation, stomach pain, headache, dizziness, trouble sleeping, increased sweating, flushing, and dry mouth or strange taste in the mouth), participants will be free to go home. If any concerning, unexpected or severe adverse events linger, the clinician will be responsible for managing the participant, in accordance with standard medical procedures (Dr. Blier).
Based on tolerability to the test dose, in consultation with the participant and the clinician, the participant will be invited to continue (or not) with the remainder of the study. A week after the test dose, eligible participants (i.e., those who tolerate the test dose, and wish to proceed) will be booked for their baseline session. Those participants who are deemed to be intolerant to the test-dose will be counted screen failures.
Body measures (e.g., weight, height, approximately 5min) will be collected and the neurocognitive battery (NIH Toolbox; approximately 30min); The neurocognitive battery, which assesses various cognitive domains (e.g., spatial memory, verbal memory, attention, inhibition) will be used to characterize the sample, and explore whether CONTRAVE® changes cognitive profiles. Participants will also undergo a session in the mock scanner situated at the BIC to ensure that they can fit into the bore of the magnet and are comfortable with neuroimaging (approximately 15min). For participants who are not comfortable with scanning/cannot fit into the scanner, they will be invited to participate in all the other elements of the proposed work (outlined below), apart from the neuroimaging.
Baseline Session (uOttawa):
Participants will complete a baseline assessment in the Behavioural and Metabolic Research Laboratory, University of Ottawa under Dr. Doucet's supervision. In his laboratory, they measure the following:
Baseline Session (The Royal):
The baseline session will take place in the Clinical EEG \& Neuroimaging Lab under the supervision of Dr. Jaworska. The following measures will be collected:
A) Electroencephalographic (EEG) \& Autonomic Nervous System (ANS) assessments:
EEG \& ANS assessments involve using a 64 or 32-channel EEG system along with additional electrodes for ANS indices like HRV and SCR. Setup by experienced personnel takes 20-30min. Data collection includes:
B) Neuroimaging:
Participants qualifying for neuroimaging will undergo a 30min brain scan at the Brain Imaging Centre using a 3T PET-MR Siemen's scanner.
Scans include:
C) Clinical measures include self-report depression and anxiety questionnaires.
D) Sleep and activity data will be collected via daily logs and accelerometry.
Intervention:
Following the completion of the baseline sessions (TheRoyal/uOttawa), participants will begin their interventions, which will include starting their medication (placebo or CONTRAVE®, based on randomization) and LEAF diet program. Participants will obtain their 4-week prescriptions from The Royal pharmacy after their in-person screening visit at The Royal. However, they will be told not to commence their treatment until they complete both baseline testing sessions and are instructed to start the medication (i.e., start of intervention week 1). The prescription for the CONTRAVE® and placebo will be filled out by the responsible physician, Dr. Judy Shiau; this will be faxed/send directly to the The Royals' pharmacy prior to the participants' arrival for their in-person screening visit.
The diet intervention will commence the same day as the start of the placebo/CONTRAVE® administration. Diet adherence and food intake will be measured daily using our online data capture system (REDCap) (approximately 1min) (carried out the same time as the sleep and adverse events questionnaire). Food journaling will be carried out through the Eat.Love platform as part of the diet coaching that will be guided by the LEAF clinic.
Monitoring:
Daily monitoring of side effects/adverse events will be conducted by a devoted research team member in Dr. Jaworska's laboratory using our REDCap during the first week of use, and weekly thereafter (i.e., mid of week 2, week 3 and week 4). A copy of all adverse events ratings for all active participants will be shared with Dr. Shiau on a weekly basis for clinical review and assessment, which Dr. Shiau will then sign, date and return to the research team. If participants experience moderate adverse events, the research personnel will inform Dr. Shiau immediately, and she can recommend dose adjustments. Participants who experience unexpected/severe adverse events will be instructed to contact the LEAF clinic to report this immediately (as per LEAF protocols). Severe adverse events will be handled as per regulated standards of care. If Dr. Shiau (responsible physician) deems that the adverse events are severe, she might advise the participant to discontinue the drug. This will be communicated to the research team (a member of the research team will thus break the blind to determine whether the drug was placebo or CONTRAVE®). Discontinuation due to adverse symptoms will be documented in the participant file.
Post-Intervention Assessment:
Following the completion of the 4-weeks of medication and diet program, participants will complete the exact same testing sessions as during the baseline sessions. The sessions will be carried out as close as possible to the end of the 4-weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current use of medication indicated in patient living with ADHD (e.g., Vivanse/Concerta) which are known to have metabolic impacts.
There are several additional exclusionary criteria, established by research personnel in Dr. Jaworska's laboratory (i.e., not part of LEAF intake) that preclude participation in the brain imaging/magnetic resonance imaging (MRI) and EEG, these include:
Ability to abstain from nicotine/tobacco and caffeine for 3h prior to the baseline testing/EEG recordings, as both substances influence EEG activity.
NOTE: If a participant cannot participate in the MRI aspect of the study (i.e., due to the above exclusion criteria), they will still be able to participate in the research study (apart from the MRI component). All MRI/EEG exclusion criteria will be established during the screening/clinical interview carried out by trained research staff from Dr. Jaworska's laboratory (details below).
One final exclusion criterion is as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A diet program + CONTRAVE®
Drug: Contrave · Behavioral: Diet Program
Diet Program + Placebo
Drug: Placebo · Behavioral: Diet Program
CONTRAVE® will be titrated up to a therapeutic dose (Naltrexone 32mg/Bupropion 360mg) over a 4-week period as per clinical guidelines, and what is typical in the LEAF clinic. Dose recommendation for CONTRAVE® is tablet based, with each tablet containing 8mg of naltrexone and 90mg of bupropion. The maximum recommended daily dose is two tablets, administered orally, twice daily (32mg/360mg), taken once in the morning and once in the evening. Tablets and dispensing schedule will be done under the oversight of The Royal pharmacy (i.e., they will instruct the participants on the dosing schedule). Medication adherence and side effects will be reported daily using our online data capture system (REDCap) (approximately 1min) starting on the evening of the first dose of administration. If adverse events are significantly concerning, there is a mechanism in place for dealing with such events.
Also known as: Naltrexone/Bupropion-NB
Placebo intervention will follow the exact same protocol in terms of tablet numbers as the CONTRAVE intervention. Generic Placebo pills will be packaged by The Royal Pharmacy into blister packs identical to Contrave.
Also known as: Vitamin Pill
All participants will receive an individualized dietary intervention with appropriate energy restriction from registered dietitians at Dr. Shiau's LEAF weight management clinic (called the 4-week BUDS program, which is offered to clients with obesity at the LEAF clinic). The program involves weekly touch points with a registered dietitian, and meal planning/coaching and integrates a partial meal replacement with a commercial shake.
MRI Modalities
Four MRI modalities will be collected during two identical 45-minute MRI session: one at baseline and another 4-weeks post placebo or Contrave. The first modality is an 8-minute resting-state functional MRI to assess brain activity at rest. Second is a 7-minute structural scan, which will allow us to explore potential changes in brain volume. Third, is a 12-minute task-based functional MRI scan where participants are presented with images of food/non-food visual cues, allowing us to assess brain activity in response to different cues. Last is a 9-minute neuromelanin scan, which allows us to visualize neuromelanin in the brain. Neuromelanin is present in brain regions implicated in the brain's reward system and is a marker of dopamine, which is highly involved in motivation and reward. This exploratory scan will help elude neuromelanin levels and locus coeruleus contrast in individuals with obesity and whether there are correlations with other neuroimaging/clinical measures.
Time frame: 4 weeks
Changes in body weight/composition
Dual Energy X-ray Absorptiometry (DEXA) will be used to measure lean mass, fat mass and percent body fat (Lunar Prodigy, GE Medical Systems)
Time frame: 4 weeks
Brain Activity EEG at Rest
Electroencephalography (EEG) at baseline and 4-weeks post placebo or Contrave. EEG will involve a 16-channel EEG system. Data collection includes resting EEG spectral power extracted from resting EEG and may include the following frequency bands: * Delta (1-4 Hz) * Theta (4-8 Hz) * Alpha (8-13 Hz) * Beta (13-30 Hz) * Gamma (\>30 Hz) Analysis: Power is typically analyzed for each frequency band.
Time frame: 4 weeks (pre and post contrave or placebo)
Brain Activity During Food Impulsivity Task
EEG-derived event-related potentials (ERPs) will be assessed during a food impulsivity task (Go/No-Go task). Specifically, N2 and P3 ERP amplitudes (µV) and latencies (ms) will be measured in response to neutral objects trial, high calorie foods and low calorie foods trials. Behavioural measures, including correct and incorrect responses (%) and reaction times (%) will be measured as secondary outcome measures.
Time frame: 4-weeks (pre and post contrave or placebo)
Brain Activity During EEFRT Task
Using the Effort Expenditure for Rewards Task (EEfRT) specific ERPs associated with reward and error processing will be obtained. Specifically, ERP amplitudes (µV) and latencies (ms) for the Stimulus Preceding Negativity (SPN), and the P3 for the easy and hard trials will be analyzed separately. The number of times participants chose the easy vs. hard trials (difficulty) is analyzed as a measure of motivation.
Time frame: 4-week (pre and post contrave or placebo)
Hedonic Mechanisms
Food palatability and appetite ratings (hunger, fullness, desire to eat, and prospective food consumption) will be measured using a 100-mm Visual analog scale (VAS) at fasting, at 0, 30, 60, 90, 120, 180 min after a standardized breakfast administered in the laboratory. Changes in both state and trait-related food craving will be assessed by the self-reported Food Craving Questionnaire. The relative reinforcing value of snack foods in relation to healthy food alternatives will also be assessed. Lunch will be served at approximately 12h30. Participants will be asked to self-select foods from a food menu. They will be instructed to eat as much as they desire of these foods. Energy intake and food preferences will then be assessed from the weight of the different foods consumed.
Time frame: 4 weeks
Mood
Self-reports of depression and anxiety symptoms will be assessed using the Beck Depression Inventory (BDI) and the Generalized Anxiety Disorder (GAD-7). These will be collected on an iPad or pen-and-paper (as per participant's preference). Data collected on an iPad will be collected using REDCap (a data collection platform used/available at The Royal, which is known to comply with privacy standards; all imputed data will be only liked with the participant code). The active drug condition (contrave) may influence mood; thus, we will track mood changes before vs. after 4-weeks of intervention. Mood scores (i.e., anxiety and depression) will be used as covariates in the analyses of behavioural and brain activity (MRI, EEG, ERP) measures listed in the primary and secondary outcomes.
Time frame: 4 weeks
Metabolic Effects
Resting and Post-Prandial Energy Expenditure: Energy expenditure (EE) will be measured fasting and after a standardized breakfast with indirect calorimetry (Vmax Encore 29N metabolic cart by SensorMedics, Yorba Linda, CA, USA). (approximately 45 min for resting and then 30 min every hour for 2 hours after a standardized breakfast, which will be provided in the laboratory).
Time frame: 4 weeks
Executive Functioning
Measured with NIH cognition toolbox.
Time frame: 4 weeks
Behavioural and EEG During a Delay Discounting Task
During a monetary delay discounting task, behavioural data will be collected and will include the number of times participants chose immediate vs delayed reward. Discount rate will also be examined. Spectral power derived from EEG data may be analyzed as a secondary measure.
Time frame: 4 weeks (pre and post contrave or placebo)
Motivation Measures
Contrave may influence motivation; thus, we will track motivation changes before vs. after 4-weeks of intervention with the placebo and CONTRAVE®. Using the Behavioural Inhibition System (BIS) and Behavioural Activation System (BAS) will assess motivation and personality-related behaviours. These measures of motivation will be assessed in correlation with measures of: * eating, hunger and food craving collected with the Food Craving Questionnaire. * EEG and ERP measures collected during the food impulsivity task, the effort expenditure task, and the delay discounting task.
Time frame: 4 week
Autonomic Nervous System Measures
Using a BIOPAC and 5 electrodes, measures of heart rate variability and skin conductance will be collected during the EEG resting state, the food impulsivity task, the effort expenditure task, and the delay discounting task. Heart rate variability and skin conductance measures will be correlated with amplitude (µv), latency (ms), and behavioural (correct responses, incorrect responses, reaction times, number of hard vs easy trials, and immediate vs delayed reward measures extracted from the previously described tasks.
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Jan 2026, 17 months after the start.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 17 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Royal's Institute of Mental Health Research